Brinda demands action against those involved in vaccine trial

Image
Press Trust of India New Delhi
Last Updated : Sep 03 2013 | 9:45 PM IST
CPI(M) leader Brinda Karat has demanded action against those involved in the trial of a vaccine which allegedly used thousands of children as guiney pigs to test their new product.
Karat demanded action in the Human Papilloma Virus (HPV) vaccine trials which was allegedly conducted on thousands of children belonging to the ST, SC and economically poor households in Andhra Pradesh and Gujarat in 2010, so that a strong message goes out to other potential exploiters of India's poor through such irregular clinical trials.
In a letter to Union Health Minister Ghulam Nabi Azad, she also urged the government to pay a compensation of Rs ten lakh to each of those who were used in the trials.
She also demanded a fine be levied by the government on PATH (Programme for Appropriate Technology in Health), the two companies and the promoter, and the Gates Foundation.
In her letter, Brinda said "it is deeply regrettable that in spite of the assurances you made on the floor of the House ...You have not taken any action whatsoever against those responsible...In the light of the report of the Standing Committee, it would be legitimate to ask is it because the health interests of poor adivasi and dalit children have little value for you that you did not act?"
She further mentioned in her letter that individuals in institutions such as the Drugs Controller General of India, Indian Council of Medical research and the National Rural Health Mission working under his Ministry have in this case been shown to have allegedly manipulated and violated rules and regulations and acted to facilitate the interests of the two foreign pharma companies.
Karat also demanded action against officials in ICMR and DCGI for permitting the project.
She also demanded action against the officials who misused the NHRM logo in Andhra Pradesh and a time-bound inquiry by an impartial agency into the process of granting marketing permission to the two pharma companies.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 03 2013 | 9:45 PM IST

Next Story